iTRAQ analysis of urinary proteins: Potential use of gelsolin and osteopontin to distinguish benign thyroid goiter from papillary thyroid carcinoma

Background: Benign thyroid goiter (BTG) and papillary thyroid carcinoma (PTC) are often interchangeably misdiagnosed. Methods: Pooled urine samples of patients with BTG (n = 10), patients with PTC (n = 9) and healthy controls (n = 10) were subjected to iTRAQ analysis and immunoblotting. Results: The...

Full description

Bibliographic Details
Main Authors: Jayapalan, Jaime Jacqueline, Lee, Cheng Siang, Lee, Ching Chin, Ng, Khoon Leong, Junit, Sarni Mat, Hashim, Onn Haji
Format: Article
Published: Elsevier 2018
Subjects:
_version_ 1825721743305605120
author Jayapalan, Jaime Jacqueline
Lee, Cheng Siang
Lee, Ching Chin
Ng, Khoon Leong
Junit, Sarni Mat
Hashim, Onn Haji
author_facet Jayapalan, Jaime Jacqueline
Lee, Cheng Siang
Lee, Ching Chin
Ng, Khoon Leong
Junit, Sarni Mat
Hashim, Onn Haji
author_sort Jayapalan, Jaime Jacqueline
collection UM
description Background: Benign thyroid goiter (BTG) and papillary thyroid carcinoma (PTC) are often interchangeably misdiagnosed. Methods: Pooled urine samples of patients with BTG (n = 10), patients with PTC (n = 9) and healthy controls (n = 10) were subjected to iTRAQ analysis and immunoblotting. Results: The ITRAQ analysis of the urine samples detected 646 proteins, 18 of which showed significant altered levels (p < 0.01; fold-change > 1.5) between patients and controls. Whilst four urinary proteins were commonly altered in both BTG and PTC patients, 14 were unique to either BTG or PTC. Amongst these, four proteins were further chosen for validation using immunoblotting, and the enhanced levels of osteopontin in BTG patients and increased levels of a truncated gelsolin fragment in PTC patients, relative to controls, appeared to corroborate the findings of the iTRAQ analysis. Conclusion: The data of the present study is suggestive of the potential application of urinary osteopontin and gelsolin to discriminate patients with BTG from those with PTC non-invasively. However, this needs to be further validated in studies of individual urine samples.
first_indexed 2024-03-06T05:55:00Z
format Article
id um.eprints-21742
institution Universiti Malaya
last_indexed 2024-03-06T05:55:00Z
publishDate 2018
publisher Elsevier
record_format dspace
spelling um.eprints-217422019-08-02T02:00:09Z http://eprints.um.edu.my/21742/ iTRAQ analysis of urinary proteins: Potential use of gelsolin and osteopontin to distinguish benign thyroid goiter from papillary thyroid carcinoma Jayapalan, Jaime Jacqueline Lee, Cheng Siang Lee, Ching Chin Ng, Khoon Leong Junit, Sarni Mat Hashim, Onn Haji R Medicine Background: Benign thyroid goiter (BTG) and papillary thyroid carcinoma (PTC) are often interchangeably misdiagnosed. Methods: Pooled urine samples of patients with BTG (n = 10), patients with PTC (n = 9) and healthy controls (n = 10) were subjected to iTRAQ analysis and immunoblotting. Results: The ITRAQ analysis of the urine samples detected 646 proteins, 18 of which showed significant altered levels (p < 0.01; fold-change > 1.5) between patients and controls. Whilst four urinary proteins were commonly altered in both BTG and PTC patients, 14 were unique to either BTG or PTC. Amongst these, four proteins were further chosen for validation using immunoblotting, and the enhanced levels of osteopontin in BTG patients and increased levels of a truncated gelsolin fragment in PTC patients, relative to controls, appeared to corroborate the findings of the iTRAQ analysis. Conclusion: The data of the present study is suggestive of the potential application of urinary osteopontin and gelsolin to discriminate patients with BTG from those with PTC non-invasively. However, this needs to be further validated in studies of individual urine samples. Elsevier 2018 Article PeerReviewed Jayapalan, Jaime Jacqueline and Lee, Cheng Siang and Lee, Ching Chin and Ng, Khoon Leong and Junit, Sarni Mat and Hashim, Onn Haji (2018) iTRAQ analysis of urinary proteins: Potential use of gelsolin and osteopontin to distinguish benign thyroid goiter from papillary thyroid carcinoma. Clinical Biochemistry, 53. pp. 127-131. ISSN 0009-9120, DOI https://doi.org/10.1016/j.clinbiochem.2018.01.008 <https://doi.org/10.1016/j.clinbiochem.2018.01.008>. https://doi.org/10.1016/j.clinbiochem.2018.01.008 doi:10.1016/j.clinbiochem.2018.01.008
spellingShingle R Medicine
Jayapalan, Jaime Jacqueline
Lee, Cheng Siang
Lee, Ching Chin
Ng, Khoon Leong
Junit, Sarni Mat
Hashim, Onn Haji
iTRAQ analysis of urinary proteins: Potential use of gelsolin and osteopontin to distinguish benign thyroid goiter from papillary thyroid carcinoma
title iTRAQ analysis of urinary proteins: Potential use of gelsolin and osteopontin to distinguish benign thyroid goiter from papillary thyroid carcinoma
title_full iTRAQ analysis of urinary proteins: Potential use of gelsolin and osteopontin to distinguish benign thyroid goiter from papillary thyroid carcinoma
title_fullStr iTRAQ analysis of urinary proteins: Potential use of gelsolin and osteopontin to distinguish benign thyroid goiter from papillary thyroid carcinoma
title_full_unstemmed iTRAQ analysis of urinary proteins: Potential use of gelsolin and osteopontin to distinguish benign thyroid goiter from papillary thyroid carcinoma
title_short iTRAQ analysis of urinary proteins: Potential use of gelsolin and osteopontin to distinguish benign thyroid goiter from papillary thyroid carcinoma
title_sort itraq analysis of urinary proteins potential use of gelsolin and osteopontin to distinguish benign thyroid goiter from papillary thyroid carcinoma
topic R Medicine
work_keys_str_mv AT jayapalanjaimejacqueline itraqanalysisofurinaryproteinspotentialuseofgelsolinandosteopontintodistinguishbenignthyroidgoiterfrompapillarythyroidcarcinoma
AT leechengsiang itraqanalysisofurinaryproteinspotentialuseofgelsolinandosteopontintodistinguishbenignthyroidgoiterfrompapillarythyroidcarcinoma
AT leechingchin itraqanalysisofurinaryproteinspotentialuseofgelsolinandosteopontintodistinguishbenignthyroidgoiterfrompapillarythyroidcarcinoma
AT ngkhoonleong itraqanalysisofurinaryproteinspotentialuseofgelsolinandosteopontintodistinguishbenignthyroidgoiterfrompapillarythyroidcarcinoma
AT junitsarnimat itraqanalysisofurinaryproteinspotentialuseofgelsolinandosteopontintodistinguishbenignthyroidgoiterfrompapillarythyroidcarcinoma
AT hashimonnhaji itraqanalysisofurinaryproteinspotentialuseofgelsolinandosteopontintodistinguishbenignthyroidgoiterfrompapillarythyroidcarcinoma